Cargando…

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer

BACKGROUND: Progesterone receptor (PgR) negative breast cancer (BC) is an aggressive subtype with poor prognosis and reduced response to endocrine treatments. Several studies have suggested that androgen receptor (AR) expression is associated with a favorable tumor biology, longer recurrence free su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tagliaferri, Barbara, Quaquarini, Erica, Palumbo, Raffaella, Balletti, Emanuela, Presti, Daniele, Malovini, Alberto, Agozzino, Manuela, Teragni, Cristina Maria, Terzoni, Andrea, Bernardo, Antonio, Villani, Laura, Sottotetti, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502860/ https://www.ncbi.nlm.nih.gov/pubmed/32994808 http://dx.doi.org/10.1177/1758835920958355

Ejemplares similares

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
por: Palumbo, Raffaella, et al.
Publicado: (2021)

Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
por: Quaquarini, Erica, et al.
Publicado: (2022)

Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy)
por: Quaquarini, Erica, et al.
Publicado: (2020)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR(+)/HER2(−) breast cancer treated with CDK4/6 inhibitors and endocrine therapy
por: Tagliaferri, Barbara, et al.
Publicado: (2023)

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
por: Palumbo, Raffaella, et al.
Publicado: (2019)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study
por: Paleari, Laura, et al.
Publicado: (2020)

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2022)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
por: Presti, Daniele, et al.
Publicado: (2019)

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer
por: Dobrescu, Andrei, et al.
Publicado: (2011)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies
por: Zhou, Chen, et al.
Publicado: (2022)

Association of +331G/A PgR Polymorphism with Susceptibility to Female Reproductive Cancer: Evidence from a Meta-Analysis
por: Chaudhary, Sanjib, et al.
Publicado: (2013)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
por: Sorbye, Sveinung W, et al.
Publicado: (2013)

Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis
por: Iadarola, Carmine, et al.
Publicado: (2019)

Treatment of Chronic Hepatitis C in a Patient Affected by Systemic Sclerosis
por: Poggi, Guido, et al.
Publicado: (2009)

Compendio informativo PGR : órgano de difusión de la Procuraduría General de la República.
Publicado: (1995)

Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer
por: Truffi, Marta, et al.
Publicado: (2021)

Nuclear Progestin Receptor (Pgr) Knockouts in Zebrafish Demonstrate Role for Pgr in Ovulation but Not in Rapid Non-Genomic Steroid Mediated Meiosis Resumption
por: Zhu, Yong, et al.
Publicado: (2015)

Prevalence of ERα-397 PvuII C/T, ERα-351 XbaI A/G and PGR PROGINS polymorphisms in Brazilian breast cancer-unaffected women
por: Giacomazzi, J., et al.
Publicado: (2012)

NTRC Effects on Non-Photochemical Quenching Depends on PGR5
por: Naranjo, Belen, et al.
Publicado: (2021)

Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel
por: Quaquarini, E., et al.
Publicado: (2019)

Identification of a Novel Mutation Exacerbated the PSI Photoinhibition in pgr5/pgrl1 Mutants; Caution for Overestimation of the Phenotypes in Arabidopsis pgr5-1 Mutant
por: Wada, Shinya, et al.
Publicado: (2021)

Prognostic Role of Pathological Complete Response in Early Stage Epithelial Solid Tumors
por: Saltalamacchia, Giuseppe, et al.
Publicado: (2023)

Progesterone Receptor (PGR) gene polymorphism is associated with susceptibility to preterm birth
por: Langmia, Immaculate Mbongo, et al.
Publicado: (2015)

PGRL2 triggers degradation of PGR5 in the absence of PGRL1
por: Rühle, Thilo, et al.
Publicado: (2021)

Chemical Structures and Pharmacological Properties of Typical Bioflavonoids in Polygonati Rhizoma (PGR)
por: Luo, Min, et al.
Publicado: (2022)

Protective Role of the PG1036-PG1037-PG1038 Operon in Oxidative Stress in Porphyromonas gingivalis W83
por: Henry, Leroy G., et al.
Publicado: (2013)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fovel4jhf5pc5p2d25fgf4t8p2